Abstract:Background: Inflammatory bowel diseases (IBDs) have several treatment modalities including immunoregulators, like cyclosporine A, an immunosuppressant that interacts with cytoplasmic cyclophilin A, and probiotics. Aims: This study explored and compared the possible role of syndecan-1 in the IBD pathogenic process as well as the effectiveness of cyclophilin A, cyclosporine A, and their combination in the management of IBDs in the presence of probiotics. Methodology: IBD was induced in a total of 112 mice equally divided between syndecan-1 knock-out (KO) and Balb/c wild-type mice, using 2% dextran sulfate sodium (DSS) followed by intraperitoneal treatment with cyclosporine A, cyclophilin A, or a combination of both. In addition, a daily dose of probiotics was given in their drinking water. The animals were monitored for clinical signs and symptoms and checked for gross pathologies in the abdomen after 3 weeks. Descending and sigmoid colon biopsies were collected and fixed for routine microscopy or frozen for protein extraction and molecular testing for IL-6, CD3, CD147, and beta 1 integrins as well as pAkt expression. Results: The data showed that the induction of IBD in the syndecan-1 KO mice was more severe at the clinical, histological, and molecular levels than in the wild type. The combined CypA-CyA treatment showed no added inhibitory effect compared to single-drug treatment in both strains. Probiotics added to the combination was more effective in the wild type and, when used alone, its inhibition of IL-6 was the highest. As for the CD147 marker, there were more suppressions across the various groups in the KO mice except for the probiotics-alone group. Concerning CD3, it was significantly increased by the CypA-CyA complex, which led to more inflammation in the KO mice. Probiotics had little effect with the combination. In relation to beta 1 integrins, the CypA-CyA combination made no significant difference from CyA alone, and adding probiotics to the combination resulted in higher beta 1 integrin expression in the KO mice. As for pAkt, it was very well expressed and upregulated in both strains treated with DSS, but the effect was much larger in the KO mice. In brief, the CypA-CyA complex showed a decrease in the expression of pAkt, but there was no added effect of both drugs. Probiotics along with the complex had a similar reduction effects in both strains, with a greater effect in the wild-type mice, while probiotics alone led to a similar reduction in pAkt expressions in both strains. Conclusions: The differential effects of CyA, CypA, probiotics, and their combinations on the various inflammatory markers, as well as the histological alterations and clinical signs and symptoms, speak in favor of a clear role of syndecan-1 in reducing inflammation. However, probiotics need to be considered after more explorations into the mechanisms involved in the presence of CypA and CyA especially since pAkt is less active in their presence.

IĸBζ is a central modulator of inflammatory arthritis pathogenesis

Electrophilic properties of itaconate and derivatives regulate the IκBζ-ATF3 inflammatory axis

IKKε Aggravates Inflammatory Response Via Activation of NF-κB in Rheumatoid Arthritis.

Use of Molecular Imaging to Quantify Response to IKK-2 Inhibitor Treatment in Murine Arthritis.

The Bispecific Antibody Aimed at the Vicious Circle of IL-1β and IL-17A, is Beneficial for the Collagen-Induced Rheumatoid Arthritis of Mice Through NF-κB Signaling Pathway.

Ikk Beta Inhibition Protects Against Bone and Cartilage Destruction in A Rat Model of Rheumatoid Arthritis

An IgD-Fc-Ig fusion protein restrains the activation of T and B cells by inhibiting IgD-IgDR-Lck signaling in rheumatoid arthritis

Jnk1 Controls Mast Cell Degranulation and Il-1 Beta Production in Inflammatory Arthritis

Microbiota-Derived Metabolites, Indole-3-aldehyde and Indole-3-acetic Acid, Differentially Modulate Innate Cytokines and Stromal Remodeling Processes Associated with Autoimmune Arthritis

A Selective Small Molecule I Kappa B Kinase Beta Inhibitor Blocks Nuclear Factor Kappa B- Mediated Inflammatory Responses In Human Fibroblast-Like Synoviocytes, Chondrocytes, And Mast Cells

The Mechanism and Potential Therapeutic Effects of Cyclosporin, Cyclophilin, Probiotics and Syndecan-1 in an Animal Model of Inflammatory Bowel Disease

IκBβ acts to inhibit and activate gene expression during the inflammatory response

The Central Inflammatory Regulator IκBζ: Induction, Regulation and Physiological Functions

Invariant Natural Killer T Cells Regulate Conventional Dendritic Cell Maturation to Re-establish Immune Tolerance to Rheumatoid Arthritis in DBA/1 Mice

Sklb023 Blocks Joint Inflammation and Cartilage Destruction in Arthritis Models Via Suppression of Nuclear Factor-Kappa B Activation in Macrophage

Anti-Inflammatory Effects of a Novel Nuclear Factor-{kappa}B Inhibitory Derivative Derived from PyrazoloPyrimidine in Three Inflammation Models

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

IκBα and IκBβ Possess Injury Context-Specific Functions That Uniquely Influence Hepatic NF-κB Induction and Inflammation

KIZ/GM114 Balances the NF-ĸB Signaling by Antagonizing the Association of TRAF2/6 with Their Upstream Adaptors

hIgDFc-Ig inhibits B cell function by regulating the BCR-Syk-Btk-NF-κB signalling pathway in mice with collagen-induced arthritis

Enhanced Mucosal Defense and Reduced Tumor Burden in Mice with the Compromised Negative Regulator IRAK-M